Clinical TrialJul 14, 2026, 07:03 AM
Atea Pharmaceuticals Initiates Phase 1 Trial for AT-587 in Hepatitis E
AI Summary
Atea Pharmaceuticals announced the initiation of a first-in-human Phase 1 clinical trial for AT-587, an oral antiviral nucleotide analog designed to treat Hepatitis E Virus (HEV) infection. HEV is a serious liver disease with no approved treatments, especially for at-risk immunocompromised populations. Preclinical data presented at EASL 2026 demonstrated AT-587's high antiviral potency against HEV, showing it to be significantly more potent than existing off-label treatments like ribavirin, and effective in an in vivo model.
Key Highlights
- Atea Pharmaceuticals initiated a first-in-human Phase 1 clinical trial for AT-587.
- AT-587 is an oral antiviral nucleotide analog targeting Hepatitis E Virus (HEV) infection.
- HEV is a serious liver disease with no currently approved treatments, particularly for immunocompromised patients.
- Preclinical data showed AT-587 is 30- to 150-fold more potent in vitro against HEV than sofosbuvir and ribavirin.
- AT-587 demonstrated in vivo efficacy against HEV genotype 3 in a gerbil model.
- The Phase 1 trial will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Price Impact
More from AVIR